Encorafenib

• CAT Number: I001079
• CAS Number: 1269440-17-6
• Molecular Formula: C22H27ClFN7O4S
• Molecular Weight: 540
• Purity: ≥95%
• Target: Raf
• Solubility: in DMSO > 10 mM
• Storage: Store at -20C
• IC50: 0.3 nM (BRaf V600E biochemical); 2 nM (A375 cell proliferation) [1]
• IUPAC Name: methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
• InChI: InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
• InChIKey: CMJCXYNUCSMDBY-ZDUSSCGKSA-N
• SMILES: CC(C)N1C=C(C(=N1)C2=CC(=CC(=C2F)NS(=O)(=O)C)Cl)C3=NC(=NC=C3)NCC(C)NC(=O)OC

Encorafenib (CAT: I001079) is a selective small molecule inhibitor of BRAF kinase. It is used in the treatment of certain types of cancer, particularly metastatic melanoma with BRAF V600E or V600K mutations. By inhibiting BRAF kinase, encorafenib prevents the activation of the MAP kinase signaling pathway, which is involved in cell growth and survival. This inhibition helps to control the growth of cancer cells harboring specific BRAF mutations. Encorafenib is typically used in combination with other targeted therapies or immunotherapies for the treatment of advanced or metastatic melanoma.

Reference

[1]. Compounds and compositions as protein kinase inhibitors . Patent WO 2011025927 A1
[2]. LGX818, From Wikipedia, the free encyclopedia